Leerink Partners Maintains Market Perform on Dentsply Sirona, Lowers Price Target to $10
Leerink Partners analyst Michael Cherny maintains Dentsply Sirona (NASDAQ:XRAY) with a Market Perform and lowers the price target from $14 to $10.
Stocks · News reference
Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11
Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — DENTSPLY SIRONA Inc. (XRAY)
Filed: 2026-10-09 AccNo: 0000818479-26-000278 Size: 152 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Piper Sandler Maintains Neutral on Dentsply Sirona, Lowers Price Target to $12
Dentsply Sirona Unit Wellspect HealthCare Announces That Its Surity Urinary Management Portfolio May Be Covered By Traditional Medicare For Eligible Beneficiaries When Medically Necessary
This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S. The Surity™ portfolio provides non-invasive